# Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B

> **NCT02288208** · PHASE1 · TERMINATED · sponsor: **TetraLogic Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Antiviral Therapy (tenofovir or entecavir)
- **DRUG:** Birinapant
- **DRUG:** Placebo (for birinapant)

## Key facts

- **NCT ID:** NCT02288208
- **Lead sponsor:** TetraLogic Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to cranial nerve palsies observed
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288208, "Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02288208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*